Hahn, A. W., Kapron, A. L., Boyle, J., Kohlmann, W., Poole, A., Gill, D. M., … Cooney, K. A. (2018). Prevalence of clinically actionable germline pathogenic variants (PVs) in advanced prostate cancer (aPC). Annals of Oncology : Official Journal of the European Society for Medical Oncology, 29, viii294. https://doi.org/10.1093/annonc/mdy284.050

Hahn, A. W., A. L. Kapron, J. Boyle, W. Kohlmann, A. Poole, D. M. Gill, S. Greenberg, et al. “Prevalence of clinically actionable germline pathogenic variants (PVs) in advanced prostate cancer (aPC).” Annals of Oncology : Official Journal of the European Society for Medical Oncology 29 (October 1, 2018): viii294. https://doi.org/10.1093/annonc/mdy284.050.

Hahn AW, Kapron AL, Boyle J, Kohlmann W, Poole A, Gill DM, et al. Prevalence of clinically actionable germline pathogenic variants (PVs) in advanced prostate cancer (aPC). Annals of oncology : official journal of the European Society for Medical Oncology. 2018 Oct 1;29:viii294.

Hahn, A. W., et al. “Prevalence of clinically actionable germline pathogenic variants (PVs) in advanced prostate cancer (aPC).” Annals of Oncology : Official Journal of the European Society for Medical Oncology, vol. 29, Oct. 2018, p. viii294. Scopus, doi:10.1093/annonc/mdy284.050.

Hahn AW, Kapron AL, Boyle J, Kohlmann W, Poole A, Gill DM, Greenberg S, Hale P, Teerlink C, Maughan BL, Cannon-Albright L, Agarwal N, Cooney KA. Prevalence of clinically actionable germline pathogenic variants (PVs) in advanced prostate cancer (aPC). Annals of oncology : official journal of the European Society for Medical Oncology. 2018 Oct 1;29:viii294.